Pre­clin­i­cal da­ta on MD An­der­son Can­cer Cen­ter-de­vel­oped drug of­fers hope for Im­bru­vi­ca-re­sis­tant man­tle cell lym­phoma pa­tients

First ap­proved in 2013 for re­lapsed/re­frac­to­ry man­tle cell lym­phoma (MCL), J&J’s Im­bru­vi­ca is now be­ing used as the first line of de­fense for the rare, ag­gres­sive, in­cur­able form of non-Hodgkin lym­phoma. How­ev­er, some pa­tients do not re­spond to the treat­ment — which sci­en­tists at­tribute to un­der­ly­ing in­trin­sic or ac­quired drug re­sis­tance. Now, re­searchers at the Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter may have de­vel­oped a drug that could help Im­bru­vi­ca-re­sis­tant pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.